Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANOPY: VYD222 for COVID-19 Prevention
NCT06039449Phase 3Completed
- Sponsor
- Invivyd
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pemivibart in coronavirus disease 2019 (COVID-19), sponsored by Invivyd. Started Sep 2023; status: completed.
02
Drugs
pemivibart
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06039449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06039449.